Document is current
Any future updates will be listed below
-
Authors
Stein, Leah
Murugesan, Karthikeyan https://orcid.org/0000-0002-2275-1126
Reeser, Julie W.
Risch, Zachary
Wing, Michele R. https://orcid.org/0000-0001-9688-0396
Paruchuri, Anoosha
Samorodnitsky, Eric
Hoskins, Emily L.
Dao, Thuy
Smith, Amy
Le, Dat
Babcook, Melissa A.
Chang, Yi Seok
Avenarius, Matthew R.
Imam, Muhammad
Freud, Aharon G.
Roychowdhury, Sameek https://orcid.org/0000-0002-8297-3038
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (UH3 CA262220)
Gateway for Cancer Research (AWD-110943)
Gateway for Cancer Research (AWD-114129)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (T32 TR004543)
- License Information
-
More Information
Article History
Received: 14 February 2024
Accepted: 28 August 2024
First Online: 17 September 2024
Competing interests
: The authors declare no competing non-financial interests but the following Competing Financial Interests: S.R. participated in Advisory Boards for Incyte Corporation (2017), AbbVie, Inc. (2017), QED Therapeutics (2018, 2019), Bayer (2020). [Health care companies) (<10,000 USD). S.R. received honoraria from IDT Integrated DNA Technologies (2017), Illumina (2018). [Technology companies]. S.R. received consulting fees from QED Therapeutics (2018, 2019) and Merck (2019). [Health care companies] (<10,000 USD). S.R. received travel reimbursement from Incyte Corporation (2019) (Less than 999 USD). K.M. employed by Foundation Medicine, Cambridge, MA, USA and holds stocks or shares from Roche Holdings AG. M.B. holds stock interests in Applied Materials, Incyte, Pfizer, and Thermo Fisher Scientific. Z.R. holds stocks or shares from Alnylam Pharmaceuticals, Geron Corporations, Lineage Cell Therapeutic, Oncolytics Biotech, Pfizer Inc., Repligen Corporation, Sangamo Therapeutics, and Viatris Inc.
